NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Sep 02 2021

· Issued by NATCO Pharma Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

NATCO Pharma Limited has issued a press release announcing the launch of NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid approved by Health Canada. This product aims to provide affordable treatment options for patients with multiple myeloma and transfusion-dependent anemia due to myelodysplastic syndromes. The launch represents a significant milestone in NATCO's efforts to expand its product portfolio and improve access to high-quality medicines in Canada.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Natco Pharma Limited has informed the Exchange regarding a press release dated September 02, 2021, titled "Natco Pharma (Canada) Inc. announces the launch of PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid��".

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases